Kelley to highlight DNA is upcoming videoconference

DNA REPAIR INTEREST GROUP VIDEO CONFERENCE: On Tuesday, December 20 at 12:30pm, a video conference will feature Apexian Pharmaceutical’s Dr. Mark Kelley. He will discuss the development of the first clinical drug targeting the DNA repair/redox signaling APE1/Ref-1; for pancreatic and other cancers The conference will be available for viewing on the internet. You will need free Real Video software. Setup details and access are … Read more…

Led by Former Lilly Exec, Apexian Out to Tackle Pancreatic Cancer

(story originally appeared on xconomy.com)  Pancreatic cancer’s standard of care includes a drug that does not help most people diagnosed with the disease. Gemcitabine (Gemzar) works in only about 10 percent of patients, says Steve Carchedi, CEO of Apexian Pharmaceuticals. Carchedi knows about gemcitabine’s limitations because he worked at Eli Lilly (NYSE: LLY) when the FDA approved the Indianapolis-based company’s drug in 1996 to treat … Read more…